PMS Registry
Company Name
AbbVie Biopharmaceuticals GmbH Taiwan Branch
Protocol Number
Title of Study
A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)
Primary Objective
The objectives of this prospective observational study are to collect the local data of clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) in AS patients after the initiation of adalimumab therapy from routine clinical practices in Taiwan.
Number of Sites
Period of Study
From:Mar 2018 to:Dec 2020
Number of Patients
IRB Approval Date
CGMH: 12 Feb 2018
BTCMF: 05 Feb 2018
NTUH: 16Jan2018
TSGH: 12 Jan 2018
Publication Plan / Date
To be determined